Gastroenterology

5-Part Tx Reporter Series:
Hepatitis B Case Files: Expert Strategies
to Optimize Therapeutic Outcomes

Part 1 | Part 2 | Part 3 | Part 4 | Part 5

This CME/CE activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

Hepatitis B Update: New Insights from EASL
- Part 1 of 5

Dear Colleague,

The 41st Annual Meeting of the European Association for the Study of the Liver (EASL) held in Vienna, Austria last April was an international gathering of the thought leaders in the field of hepatitis B. The general and parallel sessions delivered a wealth of cutting-edge research findings that will contribute now and over time to the refinement of our state-of-the-science therapeutic protocols for hepatitis B. Discussed within this newsletter are abstracts from that meeting that represent the most relevant data for today's practicing clinicians. Ongoing studies of approved anti-HBV agents, such as adefovir, (peg)interferon, and entecavir, have been extended and are yielding long-term efficacy and safety data, as well as resistance data. Agents still in development, such as telbivudine, pradefovir, and tenofovir, are progressing through the clinical development process and are accruing their foundational data. These are the developments that will most influence how we will treat HBV infection in our patients.

This Tx Reporter, "Hepatitis B Update: New Insights from EASL" is the first in a five-part series, Hepatitis B Case Files: Expert Strategies to Optimize Therapeutic Outcomes. Altogether, these five online newsletters represent one course in the Advanced Certificate Program II: Management of Chronic Hepatitis B. Watch your e-mail for a notice announcing the posting of the next issue.

Thank you for joining us!

Sincerely,

CHAIR
Robert G. Gish, MD Medical Director Liver Transplant Program Chief, Division of Hepatology and Complex GI California Pacific Medical Center San Francisco, California
Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chairs of Advanced Certificate Program II: Management of Chronic Hepatitis B, alternate to help develop content for the audioconferences. This audioconference was developed by Dr. Adrian M. Di Bisceglie and Dr. Michael W. Fried.

top

TARGET AUDIENCE

This 5-part CME/CE activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.

ACTIVITY GOAL

The goal of this 5-part CME/CE activity is to examine current and emerging strategies for diagnosing and treating patients with chronic HBV infection.

LEARNING OBJECTIVES

Evaluate the emerging safety and efficacy data of anti-HBV agents in order to develop better strategies for managing chronic HBV infection.
Integrate drug resistance data and related clinical outcomes into drug selection decisions that reduce the incidence and impact of resistance for patients with chronic HBV infection.
Incorporate relevant research findings into clinical practice to maximize opportunity for virologic or histologic response in patients with chronic HBV infection.

top

CME INFORMATION—PHYSICIANS

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

Physicians can earn up to 5 credits by completing the entire 5-part series.

CME INFORMATION—PHYSICIAN ASSISTANTS

Projects In Knowledge will issue a certificate of participation for each course the participant completes. Please check with your organization and/or society for reciprocity.

CE INFORMATION—NURSES

This activity has been approved by the American Association of Critical-Care Nurses (AACN) for a maximum of .5 contact hour. Provider #00012705.

Nurses can earn up to 2.5 credits by completing the entire 5-part series.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Robert G. Gish, MD, has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, Idun Pharmaceuticals, Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and XTL Biopharmaceuticals; is a consultant for Amgen Inc, Anadys Pharmaceuticals, Inc, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, Innogenetics, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Nucleonics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals International, XTL Biopharmaceuticals, and ZymoGenetics, Inc; and is on the speakers bureau of Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, InterMune Inc, Ortho Biotech Products LP, Schering-Plough Corporation, and Valeant Pharmaceuticals International.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

This activity will include a brief discussion of the unlabeled/unapproved use of tenofovir for the treatment of hepatitis B.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME/CE activity is supported by an educational grant from
Bristol-Myers Squibb Company.

top

1761.01

Hepatitis B Update: New Insights from EASL - Part 1 of 5

Hepatitis B Update: New Insights from EASL
- Part 1 of 5